Osteosarcoma - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 255 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Pipeline Review, H1 2017, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.

Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 14, 7, 9 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 3, 2 and 4 molecules, respectively.

Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Osteosarcoma - Overview 7
Osteosarcoma - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 15
Osteosarcoma - Therapeutics Assessment 16
Assessment by Target 16
Assessment by Mechanism of Action 19
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Osteosarcoma - Companies Involved in Therapeutics Development 26
Advaxis Inc 26
Allosteros Therapeutics Inc 26
Amgen Inc 27
AVEO Pharmaceuticals Inc 27
Bayer AG 28
Bellicum Pharmaceuticals Inc 28
Bristol-Myers Squibb Company 29
Celldex Therapeutics Inc 29
CorMedix Inc 30
CytRx Corp 30
Eisai Co Ltd 31
Eleison Pharmaceuticals LLC 31
Intezyne Technologies Inc 32
Isofol Medical AB 32
Johnson & Johnson 33
MacroGenics Inc 33
MD Biosciences GmbH 34
MediaPharma srl 34
Merck & Co Inc 35
Merck KGaA 35
Merrimack Pharmaceuticals Inc 36
Novartis AG 36
Oncolys BioPharma Inc 37
Pfizer Inc 37
Shionogi & Co Ltd 38
Teijin Pharma Ltd 38
United Therapeutics Corp 39
Osteosarcoma - Drug Profiles 40
3D-QM - Drug Profile 40
3D-QMS - Drug Profile 41
ADXS-HER2 - Drug Profile 42
aldoxorubicin hydrochloride - Drug Profile 46
AM-7209 - Drug Profile 63
AU-101 - Drug Profile 64
AV-203 - Drug Profile 65
avelumab - Drug Profile 68
axitinib - Drug Profile 77
Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 83
Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile 85
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 86
Celyvir - Drug Profile 87
cisplatin SR - Drug Profile 88
daunorubicin hydrochloride - Drug Profile 90
dihydroartemisinin - Drug Profile 91
dinutuximab - Drug Profile 92
enoblituzumab - Drug Profile 94
everolimus - Drug Profile 97
glembatumumab vedotin - Drug Profile 111
ipilimumab + nivolumab - Drug Profile 116
irinotecan hydrochloride - Drug Profile 120
IT-139 - Drug Profile 132
JNJ-64457107 - Drug Profile 134
lenvatinib mesylate - Drug Profile 136
ligerin - Drug Profile 149
MD-401A - Drug Profile 150
Modufolin - Drug Profile 151
Monoclonal Antibody for Osteosarcoma - Drug Profile 153
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 154
Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile 155
MPE-8.3 - Drug Profile 157
NT-157 - Drug Profile 158
OBP-702 - Drug Profile 160
Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer - Drug Profile 161
pazopanib hydrochloride - Drug Profile 162
pembrolizumab - Drug Profile 171
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 219
radium Ra 223 dichloride - Drug Profile 221
RSF-101 - Drug Profile 230
S-588410 - Drug Profile 232
SEN-461 - Drug Profile 234
Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma - Drug Profile 235
Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile 236
taurolidine - Drug Profile 237
Vaccine for Osteosarcoma - Drug Profile 238
VIMO-001 - Drug Profile 239
Osteosarcoma - Dormant Projects 240
Osteosarcoma - Discontinued Products 241
Osteosarcoma - Product Development Milestones 242
Featured News & Press Releases 242
Appendix 250
Methodology 250
Coverage 250
Secondary Research 250
Primary Research 250
Expert Panel Validation 250
Contact Us 250
Disclaimer 251

List of Tables

Number of Products under Development for Osteosarcoma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Osteosarcoma - Pipeline by Advaxis Inc, H1 2017
Osteosarcoma - Pipeline by Allosteros Therapeutics Inc, H1 2017
Osteosarcoma - Pipeline by Amgen Inc, H1 2017
Osteosarcoma - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
Osteosarcoma - Pipeline by Bayer AG, H1 2017
Osteosarcoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
Osteosarcoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
Osteosarcoma - Pipeline by Celldex Therapeutics Inc, H1 2017
Osteosarcoma - Pipeline by CorMedix Inc, H1 2017
Osteosarcoma - Pipeline by CytRx Corp, H1 2017
Osteosarcoma - Pipeline by Eisai Co Ltd, H1 2017
Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, H1 2017
Osteosarcoma - Pipeline by Intezyne Technologies Inc, H1 2017
Osteosarcoma - Pipeline by Isofol Medical AB, H1 2017
Osteosarcoma - Pipeline by Johnson & Johnson, H1 2017
Osteosarcoma - Pipeline by MacroGenics Inc, H1 2017
Osteosarcoma - Pipeline by MD Biosciences GmbH, H1 2017
Osteosarcoma - Pipeline by MediaPharma srl, H1 2017
Osteosarcoma - Pipeline by Merck & Co Inc, H1 2017
Osteosarcoma - Pipeline by Merck KGaA, H1 2017
Osteosarcoma - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
Osteosarcoma - Pipeline by Novartis AG, H1 2017
Osteosarcoma - Pipeline by Oncolys BioPharma Inc, H1 2017
Osteosarcoma - Pipeline by Pfizer Inc, H1 2017
Osteosarcoma - Pipeline by Shionogi & Co Ltd, H1 2017
Osteosarcoma - Pipeline by Teijin Pharma Ltd, H1 2017
Osteosarcoma - Pipeline by United Therapeutics Corp, H1 2017
Osteosarcoma - Dormant Projects, H1 2017
Osteosarcoma - Discontinued Products, H1 2017